Upload
ernest-blankenship
View
226
Download
3
Embed Size (px)
Citation preview
Up-to-date : Up-to-date : Antiplatelet Antiplatelet
Therapy for Acute Therapy for Acute Coronary Coronary SyndromeSyndrome
นพนพ. . ภาวิ�ทย์ เพ�ย์รวิ�จิ�ตรภาวิ�ทย์ เพ�ย์รวิ�จิ�ตรหน�วิย์โรคห�วิใจิหน�วิย์โรคห�วิใจิ
คณะแพทย์ศาสตรโรงคณะแพทย์ศาสตรโรงพย์าบาลรามาธิ�บดี�พย์าบาลรามาธิ�บดี�มหาวิ�ทย์าล�ย์มห�ดีลมหาวิ�ทย์าล�ย์มห�ดีล
Increasing CV MortalityIncreasing CV Mortality
0
10
20
30
40
50
60
70
80
90
Year
De
ath
ra
re p
er
10
0,0
00
po
pu
latio
ns
CVD
Accident
Cancer
AIDS
Pneumonia
Diarrhea
Bureau of Health Policy and Plan and Division of Epidemiology, MOPH
CAD: 2 Major PresentationsCAD: 2 Major Presentations
Stable anginaStable angina
Unstable angina / ACSUnstable angina / ACS
AgeAge: 55: 55 SexSex: Male: Male Past HistoryPast History: HTN: HTN OccupationOccupation: High stress: High stress ComplaintComplaint::
Chest pain when he runs Chest pain when he runs about 500 meters.about 500 meters.
Relieved with rest in 3 Relieved with rest in 3 minutes.minutes.
Occasional chest pain Occasional chest pain with stresswith stress
Case # 1: Case # 1: อาการคงท�#อาการคงท�# (stable (stable angina)angina)
ไขมั�น พั�งผืด เซล
‘‘Stable’ Angina: Predictable DiseaseStable’ Angina: Predictable Disease
AgeAge: 50: 50 SexSex: Male: Male HabitHabit: non-smoker: non-smoker Past HistoryPast History: -: -
ComplaintComplaint:: Sudden onset of chest pain Sudden onset of chest pain
while restingwhile resting No improvement after No improvement after
15minutes15minutes
What causes ‘unstable’ symptom?What causes ‘unstable’ symptom?
?
Acute Coronary SyndromeAcute Coronary Syndrome
ล�#มเล$อดี
Truths about Plaque RuptureTruths about Plaque Rupture
No warning.No warning.
Can occur after ‘normal’ EST.Can occur after ‘normal’ EST.
No precipitating cause: ?No precipitating cause: ?↑BP, ?activitiy↑BP, ?activitiy
Spectrum of ACSSpectrum of ACS
Accelerating/ New onset AnginaAccelerating/ New onset Angina
Unstable Angina, EKG-, Trop-Unstable Angina, EKG-, Trop-
UA with Trop+UA with Trop+ / NSTEMI / NQWMINSTEMI / NQWMI
STEMI / QWMI
Non ST Elevation MI
ST Elevation MI
แนวิทางการร�กษาคนไข้( แนวิทางการร�กษาคนไข้( ACSACS
Prevent plaque rupturePrevent plaque rupture StatinsStatins
Decrease ODecrease O22 need need
DecreaseDecrease platelet activation and platelet activation and aggregationaggregation
Open blocked vesselOpen blocked vessel
ย์าต(านเกล)ดีเล$อดีย์าต(านเกล)ดีเล$อดี B-blockers* B-blockers* (? mode of administration)(? mode of administration)
Ca blockers as alternativesCa blockers as alternatives NitratesNitrates OO22
MorphineMorphine Anti-coagulationAnti-coagulation ACEI*ACEI*
ย์าท�#ควิรให(ในย์าท�#ควิรให(ใน ACS ACS (NSTEMI and STEMI)(NSTEMI and STEMI)
Class I Class I
RecommendationRecommendation
If no contra-indications!
AspirinAspirin
Mechanism of actionMechanism of action:: Irreversible COX inhibitor COX inhibitor Prevents thromboxane A2 formation Diminishing platelet aggregation
IndicationIndication:: Class IA Class IA
Dosage:Dosage: 160-300mg 160-300mg
Efficacy of ASA: Reduction of Efficacy of ASA: Reduction of Death or MI in Death or MI in Unstable AnginaUnstable Angina
Wallentin LC et al JACC 1991;18:1587–1593
0.00
0.05
0.10
0.15
0.20
0.25
0 3 6 9 12
Months
Pro
bab
ility
of
de
ath
or
MI
Placebo
ASA 75 mg
Risk ratio after 1 year 0.5295% Cl 0.37–0.72 (p=0.0001)
Lytics & ASA in STEMI: ISIS-2Lytics & ASA in STEMI: ISIS-2
1. ISIS-2 Collaborative Group. Lancet 1988; 2: 349360.
12.0%
9.2% 9.4%
11.8%
13.2%
8.0%
Placebo versusstreptokinase
Placebo versus ASA 162 mg
Neitherversus both
5-w
eek
mo
rtal
ity
(%)
25%*p <0.00001
23%*p <0.00001
42%*p <0.00001
*Odds reduction
0
2
4
6
8
10
12
14
ADP AntagonistADP Antagonist
Thienopyridine derivativeThienopyridine derivative
Mechanism of action:Mechanism of action: ADP receptor antagonistADP receptor antagonist
Mode of ActionMode of Action
COX, cyclooxygenase; ADP, adenosine diphosphate; TxA2, thromboxane A2
Schafer AI Am J Med 1996;101:199–209
Clopidogrel in Unstable Angina to Prevent Clopidogrel in Unstable Angina to Prevent Recurrent Events : CURE DesignRecurrent Events : CURE Design
Double-blind treatment 3 to 12 months
ASA 75–325 mg
Clopidogrel75 mg o.d.
(~6250 patients)
Placebo1 tab o.d.
(~6250 patients)
ASA 75–325 mg
6 m
onth
vis
it9
mon
th v
isit
12 m
onth
or fi
nal v
isit
3 m
onth
vis
it
Dis
char
ge v
isit
1 m
onth
vis
it
ACSwithout ST elevation
R
N 12 50028 countries
Double-blind treatment 3 to 12 months
Day
1
Clopidogrel 300 mg loading dose
R
Plac
ebo
load
ing
dose
CURE Study Investigators Eur Heart J 2000;21:2033–2041
•Presented within 24hrs•Clinical symptoms•Ischemic EKG change
CURE : Primary EndpointCURE : Primary Endpoint
20% RRRp=0.00009n=12,562
Benefits were seen within hours and continued to increase over the 12 months
0 1 2 3 4 5 6 7 8 9 10 11 12
Months of follow-up
% of patients with recurrent ischemic event (cardiovascular death, MI, or stroke)*
0
10
14
12
4
8
6
2
Standard therapy‡
Clopidogrel + standard therapy‡
The CURE Investigators. N Eng J Med August 2001
‡including ASA
9.3%
11.4%
Overall 12 562 11.4 9.3
ST deviation + 6275 14.3 11.5ST deviation - 6287 8.6 7.0
Entry enzymes elevated + 3176 13.0 10.9Entry enzymes elevated - 9386 10.9 8.8
Diabetes + 2840 16.7 14.2Diabetes - 9722 9.9 7.9
Risk Low 4187 6.7 5.1Intermediate 4185 9.4 6.5High 4184 18.0 16.3
Rev after randomization + 4577 13.9 11.5Rev after randomization - 7985 10.0 8.1
History of rev + 2246 14.4 8.4History of rev - 10 316 10.7 9.5
Patient characteristics
0.4 0.6 0.8 1.0 1.2
RR (95% CI)
+ with condition - without condition Rev, revascularization
The CURE Investigators. N Eng J Med August 2001
Primary Outcome : SubgroupsPrimary Outcome : Subgroups
‡including ASA
2N % eventsStandard therapy‡
Clopidogrel + Standard therapy‡
PCI-CURE :PCI-CURE :Long-term EfficacyLong-term Efficacy
0.15
0.10
0.05
0.0100
040 100 200 300 400
Cum
ula
tive
ha
zard
rat
es
31% RRR31% RRRp=0.002p=0.002n=2658n=2658
Days of follow-upa b
Placebo‡ ClopidogrelClopidogrel‡‡
The CURE Investigators. Lancet August 2001
a = median time from randomization to PCI (10 days)b = 30 days after median time of PCI†up to 12 months ‡on top of standard therapy including ASA
12.6%
8.8%
Composite of CV-death or MI from randomization to end of follow-up†
Peters RJ et al. Circulation 2003;108:1682
CURE: Major Bleeding by ASA CURE: Major Bleeding by ASA DoseDose
2002 ACC/AHA UA/NSTEMI 2002 ACC/AHA UA/NSTEMI Guidelines UpdateGuidelines Update
Class I:Class I:• ASA should be administered as soon as possible after ASA should be administered as soon as possible after
presentation and continued indefinitely (IA)presentation and continued indefinitely (IA)• Clopidogrel 75 mg daily (in the absence of Clopidogrel 75 mg daily (in the absence of
contraindications) when ASA is not tolerated (IA)contraindications) when ASA is not tolerated (IA)• If early If early non-interventional approachnon-interventional approach is planned, is planned,
clopidogrel should be added to ASA as soon as possible clopidogrel should be added to ASA as soon as possible on admission and administered for at least 1 month (IA) on admission and administered for at least 1 month (IA) and for up to 9 months (IB)and for up to 9 months (IB)
• If If PCI plannedPCI planned, clopidogrel should be started and , clopidogrel should be started and continued for at least 1 month (IA) and up to 9 months continued for at least 1 month (IA) and up to 9 months in patients who are not at high risk for bleeding (IB)in patients who are not at high risk for bleeding (IB)
1. Braunwald E et al.FOR INTERNAL USE ONLY
ALBIONALBION Assessment of best Loading dose of clopidogrel to Blunt Assessment of best Loading dose of clopidogrel to Blunt platelet activation, Inflammation and Ongoing Necrosisplatelet activation, Inflammation and Ongoing Necrosis
103 patients aged 18 to 85 years103 patients aged 18 to 85 years UA NSTEMI within the 48 hours prior to randomisation. UA NSTEMI within the 48 hours prior to randomisation. 300mg, 600mg and 900mg300mg, 600mg and 900mg Blood monitored every hour during the first 6 hours then Blood monitored every hour during the first 6 hours then
at 24 hours to determine the kinetics of inhibition of at 24 hours to determine the kinetics of inhibition of platelet aggregation.platelet aggregation.
Within the first 24 hours, higher loading doses of Within the first 24 hours, higher loading doses of clopidogrel induced faster onset of action and higher clopidogrel induced faster onset of action and higher levels of inhibition of platelet aggregation than the levels of inhibition of platelet aggregation than the indicated loading dose of 300mg, in patients with ACSindicated loading dose of 300mg, in patients with ACS
Similar safety profile among different dosage groups.Similar safety profile among different dosage groups.
EuroPCR Congress in Paris on May 24EuroPCR Congress in Paris on May 24
Faster Onset of Action and Faster Onset of Action and Higher Level of Platelet InhibitionHigher Level of Platelet Inhibition
Maximum Inhibition of Platelet Aggregation (5 µM ADP)
0
5
10
15
20
25
30
35
40
45
1 2 3 4 5 6 24
Time (h)
(%) I
nhib
ition
300 mg LD600 mg LD900 mg LD
p< 0.05 vs. 300 mg LD
Shortened time to reach the highest level of inhibition of the 300 mg LD
Maximum Inhibition of Platelet Aggregation (20 µM ADP)
0
5
10
15
20
25
30
35
40
1 2 3 4 5 6 24
Time (h)
(%)
Inhi
bition
300 mg LD
600 mg LD
900 mg LD
Faster Onset of Action and Higher Level of Platelet Inhibition
p< 0.05 vs. 300 mg LD
Major Adverse Cardiac Events
300 300 mgmg
n = 35n = 35
600 mg600 mgn = 34n = 34
900 mg900 mgn = 34n = 34
Death (n)Death (n)
Non-fatal MI*(n)Non-fatal MI*(n)
Unplanned PCI (n)Unplanned PCI (n)
Hospitalization for recurrent Hospitalization for recurrent
angina (n)angina (n)
00
11
11
22
00
22
00
00
00
00
00
00
TOTAL – n (%)TOTAL – n (%) 4 4
(11.4)(11.4)
2 (5.9)2 (5.9) 00
* New Q wave or CK > 3 times the ULN
Safety
300 mg 300 mg n = 35n = 35
600 mg600 mgn = 34n = 34
900 mg900 mgn = 34n = 34
Bleeding* Day 1- Discharge Bleeding* Day 1- Discharge (n)(n)
SevereSevereModerateModerateMildMild
TOTALTOTAL
00
11
1010
1111
00
00
1010
1010
00
11
1313
1414
*GUSTO Classification
Study DesignStudy Design
*ASA=150–325 mg (if no ASA within prior 24 hours) as loading dose. Patients received heparin if they received a fibrin specific thrombolytic†All patients received ASA 75–162 mg/day plus other standard care
Study treatment until angiography (28 days) or
hospital discharge (maximum 8 days)
n=1752
n=1739
Thrombolysis, heparin and ASA*
Clopidogrel 300 mg loading dose / 75 mg QD†
Placebo†
R
Double-blind, randomized, placebo-controlled trial inpatients aged 1875 years with STEMI ≤12 hours
Clinical Follow-up at 30 days
Primary endpoint: occluded artery (TIMI flow grade [TFG] 0/1), death/MI by time of angiography
1. Sabatine MS et al. New Engl J Med 2005; 352 (available at www.nejm.org)
Angiographic Outcomes and Angiographic Outcomes and Long-term MortalityLong-term Mortality
1. Gibson CM et al. Circulation 2002; 105: 19091913.
0
2
4
6
8
10
12
14
16
0
2
4
6
8
10
12
14
16
TFG 0/1
2-ye
ar m
ort
alit
y (%
)
14.5%
TFG 2/3 TMPG 0/1 TMPG 2/3
6.4%
4.8%
9.1%
HR: 0.41 (p=0.001) HR: 0.51 (p=0.038)
TIMI flow grade TIMI myocardial perfusion grade*
*90 minute angiogram in TIMI 10b trial; HR=hazard ratio
Primary endpoint:Primary endpoint:• CompositeComposite
• % of occluded infarct related artery (TFG 0/1) on pre-% of occluded infarct related artery (TFG 0/1) on pre-discharge angiogramdischarge angiogram
• Death or MI before CAGDeath or MI before CAG• Death or MI by hospital discharge (maximum 8 days) if no Death or MI by hospital discharge (maximum 8 days) if no
angiography performedangiography performed
Study EndpointsStudy Endpoints
*CV death, MI, stroke or recurrent ischemia leading to urgent target vessel revascularization
FOR INTERNAL USE ONLY1. Sabatine MS et al. New Engl J Med 2005; 352
Clopidogrel Improved PerfusionClopidogrel Improved Perfusion
*Based on odds of an occluded infarct-related artery (TFG 0/1), death or MI by angiography for clopidogrel versus placebo (OR: 0.64 [0.53 to 0.76]; p <0.001)
Placebo(n=1739)
Clopidogrel(n=1752)
21.7
15.0
5
10
15
20
25P
rim
ary
end
po
int*
(%
)36% reduction*
p <0.001
1. Sabatine MS et al. New Engl J Med 2005; 352 (available at www.nejm.org)
CLARITY: CLARITY: Reduction of Primary Endpoint by 36%Reduction of Primary Endpoint by 36%
ClopidogrelClopidogrel PlaceboPlacebo Odds ratioOdds ratio
(n=1752) (n=1752) (n=1739)(n=1739) (95% CI)(95% CI) p value p value
Primary endpoint (%)Primary endpoint (%) TFG 0/1, MI/deathTFG 0/1, MI/death 15.015.0 21.721.7 0.64 (0.530.64 (0.530.76)0.76) <0.001<0.001
Components (%)Components (%) TFG 0/1TFG 0/1 11.711.7 18.418.4 0.59 (0.480.59 (0.480.72)0.72) <0.001 <0.001 Recurrent MIRecurrent MI 2.52.5 3.63.6 0.70 (0.470.70 (0.471.04)1.04) 0.080.08 DeathDeath 2.62.6 2.22.2 1.17 (0.751.17 (0.751.82)1.82) 0.490.49
FOR INTERNAL USE ONLY1. Sabatine MS et al. New Engl J Med 2005; 352
Number of Odds Event rates (%)Characteristic patients reduction Clopidogrel Placebo
OVERALL 3491 36 15.0 21.7Age
<65 years 2466 42 13.2 21.065 years 1015 22 19.0 23.1
GenderMale 2796 35 14.5 20.8Female 685 38 16.9 24.7
Infarct locationAnterior 1416 33 15.0 20.7Non-anterior 2065 38 15.0 22.2
FibrinolyticFibrin-specific 2397 31 14.7 20.1Non-fibrin specific 1084 44 15.7 24.9
Predominant heparinLMWH 1429 31 11.4 15.7UFH 1431 42 17.8 27.1None 621 26 17.1 21.9
1.00.4 0.6 0.8 1.2 1.6Clopidogrel better Placebo better
Primary Endpoint: SubgroupsPrimary Endpoint: Subgroups
1. Sabatine MS et al. New Engl J Med 2005; 352
CLARITY :CLARITY : Clinical Events at 30 Days Clinical Events at 30 Days
CV death, MI or recurrent ischemia leading to urgent revascularization
Time (days)
Inci
den
ce o
f cl
inic
al e
nd
po
ints
(%
)
0
5
10
15
0 5 10 15 20 25 30
PlaceboClopidogrel 20%*
p=0.03
1. Sabatine MS et al. New Engl J Med 2005
SafetySafetyClopidogrelClopidogrel PlaceboPlacebo(n=1733) (n=1733) (n=1719)(n=1719) p valuep value
Primary bleeding endpointPrimary bleeding endpoint (%) (%) TIMI major TIMI major 23 (1.3)23 (1.3) 19 (1.1)19 (1.1) 0.640.64
Secondary bleeding endpointsSecondary bleeding endpoints (%) (%) TIMI minor TIMI minor 17 (1.0)17 (1.0) 9 (0.5)9 (0.5) 0.170.17 TIMI major or minor TIMI major or minor 40 (2.3)40 (2.3) 28 (1.6)28 (1.6) 0.180.18 Intracranial hemorrhageIntracranial hemorrhage 8 (0.5)8 (0.5) 12 (0.7)12 (0.7) 0.380.38
Bleeding through 30 daysBleeding through 30 days (%) (%) TIMI major TIMI major 33 (1.9)33 (1.9) 30 (1.7)30 (1.7) 0.800.80 TIMI minor TIMI minor 27 (1.6)27 (1.6) 16 (0.9)16 (0.9) 0.120.12 TIMI major or minor TIMI major or minor 59 (3.4)59 (3.4) 46 (2.7)46 (2.7) 0.240.24
FOR INTERNAL USE ONLY1. Sabatine MS et al. New Engl J Med 2005; 352
1. Chen ZM et al. ACC 2005.
COMMIT/CCS-2: COMMIT/CCS-2: CCllOOpidogrel pidogrel and and MMetoprolol in etoprolol in MMyocardial yocardial
IInfarction nfarction TTrialrial
Double-blind treatment until hospital discharge or for a maximum of 4 weeks
(n ~ 23,000)
n=~46,000R
Patients with acute STEMI 24 hours
* All patients received a background of ASA 162mg/day during the study
(2 2 Factorial with metoprolol)
Study DesignStudy DesignClopidogrel 75 mg QD*
Placebo*
(n ~ 23,000)
1. Chen ZM et al. ACC 2005.
0 7 14 21 280
1
2
3
4
5
6
7
8
9
10
Days since randomization(up to 28 days)
Clopidogrel(9.3%)
Placebo (10.1%)
Eve
nts
(%
)RRR=9%
P=0.002
COMMIT: Composite EndpointCOMMIT: Composite Endpoint(Death, MI, or Stroke)(Death, MI, or Stroke)
FOR INTERNAL USE ONLY1. Chen ZM et al. ACC 2005.
0 7 14 21 280
1
2
3
4
5
6
7
8
9
Days since randomization (up to 28 days)
Clopidogrel(7.5%)
Placebo(8.1%)
RRR=7%p=0.03
Mo
rtal
ity
(%)
COMMIT: MortalityCOMMIT: Mortality
1. Chen ZM et al. ACC 2005.
COMMIT: SummaryCOMMIT: Summary
• For STEMI, ASA + clopidogrel 75mg OD + Lytic:For STEMI, ASA + clopidogrel 75mg OD + Lytic:• 7% reduction mortality7% reduction mortality• No significant excess in TIMI major bleeding or No significant excess in TIMI major bleeding or
ICHICH
FOR INTERNAL USE ONLY
GP IIb/IIIa Receptor AntagonistsGP IIb/IIIa Receptor Antagonists
EptifibatideEptifibatide TirofibanTirofiban AbciximabAbciximab
A murine monoclonalantibody that completely blocks
the binding of fibrinogen to platelets produces
a thrombasthenic-like state in normal platelets and binds to
glycoproteinsIIb and/or IIIa. J Clin Invest 1983
Coller BS, Peerschke EI, Scudder LE, Sullivan CA. Fc fragment of murine monoclonal antibody against Gp2b3a, 7E3,
was removed to prevent immunogenicity and Fab fragments joined with the constant regions of human immunoglobulin, forming a chimeric compound (abciximab, or c7E3).
RGD sequence
Gp IIb/IIIa in ACSGp IIb/IIIa in ACS
Gp IIb/IIIa blockers are recommended Gp IIb/IIIa blockers are recommended (Class I) for UA/NSTEMI treated with (Class I) for UA/NSTEMI treated with
interventional approach.interventional approach.
For non-interventional patients with For non-interventional patients with ongoing ischemia (Class II)ongoing ischemia (Class II)
ISAR-REACT:ISAR-REACT:30-d adverse reactions in low-to-moderate risk undergoing 30-d adverse reactions in low-to-moderate risk undergoing
PCI after 600mg Clopidogrel loading dosePCI after 600mg Clopidogrel loading dose
Antiplatelet therapy is essential in the management of Antiplatelet therapy is essential in the management of patients with ACSpatients with ACS
Medically treatedMedically treated Percutaneous interventionPercutaneous intervention New studies support expanding role of ADP New studies support expanding role of ADP
antagonists in the management of STEMIantagonists in the management of STEMI
ConclusionsConclusions
FOR INTERNAL USE ONLY1. Chen ZM et al. ACC 2005.
Thank you for your Thank you for your attention.attention.